



## **C4X Discovery chosen as new name for Conformetrix**

### **Rebranding reflects value of company's technology in drug discovery**

**Manchester, UK, July 8 2013** – To reflect an increased recognition of the impact of its 3D NMR technology on drug discovery and optimisation, C4X Discovery has been chosen as the new name for Conformetrix.

Since its formation in 2008, the company has extensively refined its dynamic NMR technology and applied it to drug discovery and optimisation both internally and in partnership with the pharmaceutical and biotechnology industry. In using its technology to determine the 3D structures of a wide range of molecules believed to have therapeutic relevance, it has generated a significant database of structures and understanding of effective drug discovery and design. Over the next few months, C4X Discovery expects to announce the publication of key structures from its database, as well as upgrades to its technology which will enhance its speed of use and integration into partners' R&D programmes.

Dr Clive Dix, Chairman of C4X Discovery, said, 'The data generated by the application of our technology to a broad range of structures underlines its potential to revolutionise the efficiency of drug discovery and optimisation across pipelines, and our new name reflects this. C4X Discovery is continuing to make exceptional progress with its internal pipeline and collaborators.'

--ENDS--

#### **For further information please contact:**

##### **C4X Discovery Ltd**

Sam Williams, CEO

+44 (0)7881 588947

Emma Palmer Foster, Strategic Communications Consultant

+44 (0)7880 787185

communications@c4xdiscovery.com

#### **About C4X Discovery Ltd**

C4X Discovery is a Manchester-based company focused on optimising drug discovery and design. It was founded in 2008 as a spin-out from the University of Manchester. The company uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. Since C4X Discovery's NMR technology shows what shapes molecules adopt when active, it provides high-quality templates for drug discovery and design, and valuable information for drug candidate optimisation. In addition, the data is generated faster and more cheaply than by standard techniques such as X-ray crystallography. C4X Discovery has solved structures

for large pharmaceutical companies, as well as developing proprietary drug programmes, and signed a collaboration with AstraZeneca in 2012. It has been funded since inception by life science investor Aquarius Equity Partners. [www.c4xdiscovery.com](http://www.c4xdiscovery.com).

**About C4X Discovery's technology**

C4X Discovery's NMR technology determines accurate three-dimensional structures - or conformations - of drug molecules in their bioactive states. This is achieved without the need for traditional structural information regarding the protein target of each drug, thereby providing researchers with valuable information on how development-stage compounds are likely to interact with their targets. This new information should improve the efficiency and quality of the lead identification, lead optimisation and candidate selection stages of drug discovery programmes.